EGRX earnings

WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than one business day after the due date of its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023 (the "Form 10-Q"), and expects to file its Form 10-Q by November 14, 2023, prior to the expiration of the extension period provided b

WOODCLIFF LAKE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its third quarter 2023 financial results on Thursday, November 9, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: DateTimeToll free (U.S.)InternationalThursday, November 9, 2023 8:30 a.m. ET800-343-4136203-518-9843  Webcast (live and replay)www.eagleus.com, under the "Investor Relations" section   A replay of the conference call will be available for two weeks after the ca

• Total revenue for Q2 2023 was $64.6 million • Q2 2023 net income was $0.39 per basic and diluted share and adjusted non-GAAP net income1 was $1.18 per basic and diluted share • Q2 2023 net income was $5.2 million • Q2 2023 adjusted non-GAAP EBITDA1 was $20.7 million • Gross margin was 74% for the first half of 2023, up from 73% for the first half of 2022 • Adjusted non-GAAP gross margin1 was 83% for the first half of 2023, up from 74% for the first half of 2022 • Gross profit in its oncology business was $41.9 million in the second quarter of 2023 compared with $38.7 million in the prior year period, representing gross margin of 80% and 72%, respectively • Adjusted non-GAAP gross pr

WOODCLIFF LAKE, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its second quarter 2023 financial results on Tuesday, August 8, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: DateTuesday, August 8, 2023Time8:30 a.m. ETToll free (U.S.)800-343-4136International203-518-9814 Webcast (live and replay) www.eagleus.com, under the "Investor Relations" section A replay of the conference call will be available for two weeks after the call's comp

Total revenue for Q1 2023 was $66.3 million, compared to $115.9 million in Q1 2022Q1 2023 net income was $0.44 per basic and diluted share and adjusted non-GAAP net income1 was $1.27 per basic and $1.26 per diluted shareQ1 2023 adjusted non-GAAP EBITDA of $22.3 millionQ1 2023 net sales of PEMFEXY® totaled $22.9 million; Eagle estimates that it has an approximate 15% share in commercial (non-340B) pemetrexed market for the second quarter of 2023 to date2BENDEKA®3 and BELRAPZO®4 - both ready-to-dilute ("RTD") products — combined maintained approximately 89% share of the bendamustine U.S. market for the first quarter of 2023 compared to approximately 90% historically5Company reaffirms full year

WOODCLIFF LAKE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its first quarter 2023 financial results on Tuesday, May 9, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: Date Tuesday, May 9, 2023Time 8:30 a.m. ETToll free (U.S.) 800-274-8461International  203-518-9814   Webcast (live and replay) www.eagleus.com, under the "Investor Relations" section A replay of the conference call will be available for two weeks after the call's completion

• Q4 2022 net income was $0.63 per basic and $0.62 per diluted share and adjusted non-GAAP net income was $1.11 per basic and $1.10 per diluted share1 • Total revenue for Q4 2022 was $60.7 million, compared to $42.3 million in Q4 2021 • FY 2022 net income was $2.76 per basic and $2.73 per diluted share and adjusted non-GAAP net income was $7.87 per basic and $7.79 per diluted share1 • FY 2022 revenue was $316.6 million compared to $171.5 million in FY 2021 • FY 2022 net sales of PEMFEXY® totaled $67.5 million, and were $12.1 million in Q4 2022, representing a 6% U.S. market share in community oncology at the end of Q4 2022; already captured a 10% share through February 2023; anticipate e

WOODCLIFF LAKE, N.J., March 03, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, before the market opens.Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: Date: Monday, March 13, 2023 Time: 8:30 a.m. ET Toll free (U.S.) 800-445-7795 International 785-424-1789    Webcast (live and replay) www.eagleus.com, under the "Investor Relations" section A replay of the conference call will be available for tw

WOODCLIFF LAKE, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. is re-issuing in its entirety its earnings press release for the third quarter ended September 30, 2022, originally issued on November 7, 2022 at 6:50 am ET, to correct errors in the presentation of certain line items in the financial statements included therein and corresponding references to such items in the narrative disclosure as described in the Company's Form 8-K/A filed on November 9, 2022. All other information in the earnings press release remains unchanged, including adjusted non-GAAP net income, adjusted non-GAAP basic and diluted earnings per share and adjusted non-GAAP EBITDA. The corrected

Q3 2022 net loss was $(0.27) per basic and diluted share and adjusted non-GAAP net income was $1.13 per basic and $1.12 per diluted share1Total revenue for Q3 2022 was $65.9 million, compared to $39.9 million in Q3 2021Nine-month 2022 net income was $2.41 per basic and $2.38 per diluted shareNine-month 2022 adjusted non-GAAP earnings per diluted share1 more than doubled to $6.69 from full year 2021 adjusted non-GAAP earnings per diluted share, outperforming any full year in the Company's historyNine-month 2022 revenue of $255.9 million exceeds full year 2021 revenue of $171.5 millionNine-month 2022 net sales of vasopressin and PEMFEXY combined totaled $114.9 millionBENDEKA®2 and BELRAP

WOODCLIFF LAKE, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its 2022 third quarter financial results on Monday, November 7, 2022, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: Date Monday, November 7, 2022Time 8:30 a.m. ETToll free (U.S.) 800-343-4849International 785-424-1699   Webcast (live and replay) www.eagleus.com, under the "Investor Relations" section A replay of the conference call will be available for two weeks after the cal

•   Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share •   Total revenue for Q2 2022 was $74.1 million, compared to $48.1 million in Q2 2021, primarily reflecting product sales of vasopressin and PEMFEXY® •   First half 2022 adjusted non-GAAP earnings per diluted share1 more than doubled to $5.60 from full year 2021 adjusted non-GAAP earnings per diluted share, outperforming any full year in the Company's history •   First half 2022 revenue of $190 million exceeds full year 2021 revenue of $171.5 million •   First half 2022 net sales of vasopressin and PEMFEXY combined totaled $99.4 million •   Cash a

WOODCLIFF LAKE, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its 2022 second quarter financial results on Tuesday, August 9, 2022, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: DateTuesday, August 9, 2022Time8:30 a.m. ETToll free (U.S.)800-445-7795International203-518-9843  Webcast (live and replay)www.eagleus.com, under the "Investor Relations" section   A replay of the conference call will be available for two weeks after the call

Q1 2022 net income was $3.47 per basic and $3.41 per diluted share and adjusted non-GAAP net income* was $4.10 per basic and $4.04 per diluted shareQ1 2022 total revenue was $115.9 million, up from $41.2 million in Q1 2021Achieved sales of $34.3 million of vasopressin, with prior four weeks average market share of 24% per IQVIA dataAchieved sales of $37.2 million of PEMFEXY™ (pemetrexed for injection), a branded alternative to ALIMTA®Agreed to terms to acquire Acacia Pharma Group plc, including two FDA-approved, NCE hospital-based products; expected to close in June 2022, subject to satisfaction of closing conditionsRemains on track to support submission of new drug application later this mo

WOODCLIFF LAKE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its 2022 first quarter financial results on Monday, May 9, 2022, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows:   DateMonday, May 9, 2022Time8:30 a.m. ETToll free (U.S.)800-891-3840International203-518-9544  Webcast (live and replay)www.eagleus.com, under the "Investor Relations" section   A replay of the conference call will be available for two weeks after the call's complet

Expects to add two U.S. Food and Drug Administration ("FDA")-approved, new chemical entities ("NCEs") with patent life into 2031 and expand acute care footprintCommercialized assets, BARHEMSYS® (amisulpride for injection) and BYFAVO® (remimazolam for injection), represent a strong strategic fit with Eagle's specialized hospital-based salesforceAddressable market for the two products combined is estimated to be $3.1 billion per year1Anticipates significant financial synergies from the proposed transactionCompany to hold investor conference call to discuss proposed transaction on Thursday, March 31, 2022, at 8:30am ET WOODCLIFF LAKE, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceut

Q4 2021 net loss was $(0.48) per basic and diluted share and adjusted non-GAAP net income* was $0.87 per basic and $0.85 per diluted shareFY 2021 net loss was $(0.66) per basic and diluted share and adjusted non-GAAP net income* was $2.64 per basic and $2.59 per diluted shareEarly trends1 indicate that Q1 2022 revenue is expected to be in the range of $120 million - $130 million and adjusted non-GAAP earnings per share* in the range of $3.80 - $4.10Commenced shipment of vasopressin, a generic alternative to Vasostrict®, with 180 days of marketing exclusivityAnnounced commercial availability of novel product, PEMFEXY™ (pemetrexed for injection), a branded alternative to ALIMTA®On track to sup

WOODCLIFF LAKE, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its 2021 fourth quarter and full year financial results on Monday, March 7, 2022, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: DateMonday, March 7, 2022Time8:30 a.m. ETToll free (U.S.)866-831-8713International203-518-9822  Webcast (live and replay)www.eagleus.com, under the "Investor Relations" section A replay of the conference call will be available for one week after the call's co

Q3 2021 net loss was $0.43 per basic and diluted share and adjusted non-GAAP net income was $0.57 per basic and $0.56 per diluted share Expect to receive approval for Abbreviated New Drug Application ("ANDA") for vasopressin; December 15, 2021 GDUFA date Received favorable district court decision that Eagle's proposed vasopressin product does not infringe any of the patents Par asserted against Eagle Entered into worldwide licensing agreement for CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe bacterial pneumonia Licensed U.S. commercial rights to landiolol, a beta-1 adrenergic blocker, a leading hospital emergency use prod

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its 2021 third quarter financial results on Tuesday, November 9, 2021, before the market opens. Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: Date Tuesday, November 9, 2021 Time 8:30 a.m. ET Toll free (U.S.) 866-342-8591 International 203-518-9822   Webcast (live and replay) www.eagleus.com, under the "Investor Relations" section A replay of the conference call will be available for one week after the call's completion by dialing 800-

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") will host an investor event, led by Scott Tarriff, Chief Executive Officer, and Judi Ng-Cashin, Chief Medical Officer, and will feature other guest speakers, to discuss the CAL02 opportunity, the current treatment landscape and the unmet medical need in treating patients with severe pneumonia as follows: Date           Thursday, September 9, 2021 Time           8:30 A.M. EDT Toll free (U.S.)           877-876-9174 International           785-424-1669 Webcast (live and replay)           www.eagleus.com, under the

-- CAL02 neutralizes toxic virulence effectors ("VEs") produced by bacteria; VEs play a decisive role in the development of long-term, severe and fatal pneumonia complications -- -- Results of first-in-human1 clinical trial published in The Lancet Infectious Diseases, where accompanying comments characterized CAL02 as "One step closer to precision medicine for infectious diseases," describing "this study a medical breakthrough" -- -- Potential to address significant unmet need in the treatment of severe pneumonia, which accounts for 2.4 million deaths per year globally -- -- Eagle anticipates ten years of regulatory exclusivity -- -- Eagle to host CAL02 Investor Event on September 9, 20

Q2 2021 net income was $0.28 per basic and $0.27 per diluted share and adjusted non-GAAP net income was $0.95 per basic and $0.93 per diluted share Announced licensing agreement for U.S. commercial rights to Landiolol, a beta-1 adrenergic blocker and a leading hospital emergency use product in Europe and Japan Responded to CRL for vasopressin and anticipates commercial launch by year-end; vasopressin patent trial decision expected around mid-September FDA maintained Priority Review for the Company's Abbreviated New Drug Application ("ANDA") for vasopressin and assigned a GDUFA date of December 15, 2021 Expects approximately $20-$25 million from combined royalty and milestone revenue nex

Eagle Pharmaceuticals, Inc. ("Eagle" or the "Company") (NASDAQ:EGRX) today announced that the Company will release its 2021 second quarter financial results on Monday, August 9, 2021, before the market opens. Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: Date     Monday, August 9, 2021 Time     8:30 a.m. ET Toll free (U.S.)     877-876-9173 International     785-424-1667 Webcast (live and replay)     www.eagleus.com, under the "Investor Relations" section A replay of the conference call will be available for one week after the call's completion by di